German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Rahbar, Kambiz; Ahmadzadehfar, Hojjat; Kratochwil, Clemens; Haberkorn, Uwe; Schäfers, Michael; Essler, Markus; P. Baum, Richard; Kulkarni, Harshad; Schmidt, Matthias; Drzezga, Alexander; Bartenstein, Peter; Pfestroff, Andreas; Luster, Markus; Lützen, Ulf; Marx, Marlies; Prasad, Vikas; Brenner, Winfried; Heinzel, Alexander; M. Mottaghy, Felix; Ruf, Juri; T. Meyer, Philipp; Heuschkel, Martin; Eveslage, Maria; Bögemann, Martin; P. Fendler, Wolfgang; J. Krause, Bernd

doi:10.2967/jnumed.116.183194

Public

German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Published in Journal of Nuclear Medicine • Oct 20, 2016

Authors:

Kambiz Rahbar

Hojjat Ahmadzadehfar

Clemens Kratochwil

Abstract

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the German Society of Nuclear Medicine, a retrospective multicenter data analysis was started in 2015 to evaluate efficacy ...

Subject

Medicine

Prostate cancer

Toxicity

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!